Post by healthy11 on Aug 2, 2022 14:01:40 GMT -5
www.medicalnewstoday.com/articles/fda-approves-non-stimulant-medication-qelbree-for-adults-with-adhd#ADHD-treatment-options
The United States Food and Drug Administration (FDA) has expanded its approval of a non-stimulant medication, viloxazine extended-release capsules, also known as Qelbree, for treating attention deficit hyperactivity disorder (ADHD) in adults. Qelbree is the first non-stimulant drug approved for treating ADHD in adults in 20 years. The FDA initially approved Qelbree in 2021 for treating ADHD in children ages 6–17. People with ADHD take the medication once per day, and it is available in an extended-release capsule.
If you or your child is taking Qelbree (viloxazine) please share your experiences with it in this discussion thread. If you or your child previously took a different ADHD medication, it would also be helpful to know how Qelbree compares.
The United States Food and Drug Administration (FDA) has expanded its approval of a non-stimulant medication, viloxazine extended-release capsules, also known as Qelbree, for treating attention deficit hyperactivity disorder (ADHD) in adults. Qelbree is the first non-stimulant drug approved for treating ADHD in adults in 20 years. The FDA initially approved Qelbree in 2021 for treating ADHD in children ages 6–17. People with ADHD take the medication once per day, and it is available in an extended-release capsule.
If you or your child is taking Qelbree (viloxazine) please share your experiences with it in this discussion thread. If you or your child previously took a different ADHD medication, it would also be helpful to know how Qelbree compares.